Genmab — April 2020

[E_L]

Blood Cancer Journal: DuoHexaBody-CD37, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies https://www.nature.com/articles/s41408-020-0292-7

[E_L]

follows the new trial @gentogen posted yesterday

[E_L]

DuoHexaBody-CD37 not only outperformed all other CD37 antibody variants evaluated in ex vivo CDC assays using primary CLL patient samples, but also outperformed approved CD20 mAbs rituximab, ofatumumab and obinutuzumab.

[E_L]

the threshold for complement activation by DuoHexaBody-CD37 might be lower, which could result in enhanced anti-tumor efficacy in clinical settings. This could be of specific interest for patients who no longer respond to CD20 mAb treatment regimens,

[E_L]

[it was also] shown to efficiently engage with FcγRs in mediating ADCC and ADCP, indicating the mechanism of action of DuoHexaBody-CD37 is multifaceted.

[E_L]

induced significant inhibition of tumor growth

[E_L]

Combinations of DuoHexaBody-CD37 with anti-CD20 antibodies could be of particular interest

[E_L]

the enthusiasm here is overwhelming

[bongobob]

Yes, very impressive article. Truly a leap frog candidate. No competition. I was wondering if we could see this in MS like Ofa

[Sukkeralf]

E L could it be combined with CD20/CD3 or just CD20 antibodies - again maybe important for a epcoritamab deal if DuoHexa-CD37 should be included

[Sukkeralf]

But maybe Genmab want to see some data before they decide if it should part
nered up

[E_L]

interesting thoughts...
-from both

[Sukkeralf]

My preferred partner would be Novartis or Janssen at the moment

[E_L]

i think we could all be happy with those

[troldmanden]

Helst ikke JnJ. Ikke for mange store æg i samme kurv....

[gentogen]

In the article (looks absolutely great) they also have a reference to this one; "CD20 And CD37 Antibodies Synergize To Activate Complement By Fc-Mediated Clustering". It also looks very promising: http://www.haematologica.org/content/104/9/1841

[gentogen]

By the way, it looks like the first author Simone Oostindie is not only at Genmab but also works at the same place as Paul Parren

[E_L]

it is a University Medical Centre, in Leiden. Parren is a Professor there, maybe she is doing her Phd with him there

[E_L]

Usmani starts a small trial of Dara-Pembro for Heavily pre-treated Multiple Myeloma Patients https://clinicaltrials.gov/ct2/show/NCT04361851?term=genmab+OR+daratumumab+OR+darzalex+OR+ofatumumab+OR+Teprotumumab+OR+Tisotumab+OR+camidanlumab+OR+Enapotamab+OR+ADCT-301+OR+duobody&lupd_s=04%2F28%2F2020&draw=2&rank=5

[gentogen]

En detalje fra artikel: We speculate that combinations of DuoHexaBody-CD37 with pro-apoptotic PI3K-δ-inhibitors such as idelalisib may work synergistically,